Skip to main content

C5i, C5 inhibitor; EVH, extravascular hemolysis; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; GPI, glycosylphosphatidylinositol; Hb, hemoglobin; IVH, intravascular hemolysis; PIG-A, phosphatidylinositol glycan class A; PNH, paroxysmal nocturnal hemoglobinuria; RBC, red blood cell.

1. Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341-348. doi:10.1016/j.htct.2020.06.006
2. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101:251-263. doi:10.1007/s00277-021-04715-5
3. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009;113(26):6522-6527. doi:10.1182/blood-2009-03-195966
4. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804-2811. doi:10.1182/blood-2014-02-522128
5. Empaveli. Prescribing information. Apellis Pharmaceutical, Inc.
6. Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and
eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020;15(9):e0237497. doi:10.1371/journal.pone.0237497
7. Soliris. Prescribing information. Alexion Pharmaceuticals, Inc.
8. Ultomiris. Prescribing information. Alexion Pharmaceuticals, Inc.